Jim Cramer outlined the stocks and events he will be watching next week, and has his eye on one cohort.
Biotech stocks have seen a big bounce in the past few weeks, as the group hits its highest level since January. Talking biotech, with David Seaburg, Cowen, and Chad Morganlander, Stifel Nicolaus.
CNBC's Landon Dowdy takes a look at the best performing sectors and stocks in the S&P 500 this summer so far.
Jim Cramer identified four groups to embrace and avoid in the market, including one with a powerful growth story.
The $75 billion Biogen may be vulnerable to a takeover, but it makes a risky target at a likely value approaching $90 billion.
CNBC's Tyler Mathisen looks at good, bad and ugly stocks, including Biogen, Qorvo and more.
Biotech hits a 6-month high. The "Fast Money Halftime Report" traders discusses whether they think it's time to buy biotech.
Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell.
Ronny Gal, Sanford C. Bernstein, discusses the potential of a takeover deal for Biogen.
Barbara Ryan, Partner at Barbra Ryan Advisors, discusses the biotech and pharma space as rumors fly on a takeover deal for Biogen.
Geoff Porges, Leerink Partners Managing Director & Senior Biotech Analyst, discusses the news that Biogen is a possible takeover target for the likes of Merck and Allergan.
Biogen shares soared on reports the company has drawn takeover interest from rival companies, the Wall Street Journal said.
Sources say Allergan is unlikely to pursue Biogen deal. CNBC's Meg Tirrell reports the details. The "Fast Money" traders weigh in.
The Fast Monet Trader's discuss the surge in Biogen after talk of a possible buyout.
CNBC's Bob Pisani looks at the day's market action.
CNBC's Meg Tirrell discusses Biogen drawing interest from Merck and Allergan, as possible acquisition, according to Dow Jones.
Biogen gets interest from Merck and Allergan, according to Dow Jones.
The "Fast Money" traders share their first moves for the market open.
Jim Cramer provided his long-term view of the market, as the notoriously difficult month of August begins.
Jim Cramer spoke with the CEO of Ionis Pharmaceuticals, which skyrocketed on Monday following positive data its SMA drug.